Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of CAMZYOSTM (mavacamten capsules) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients. Hypertrophic Cardiomyopathy (HCM) is a chronic disease where the heart's walls become thickened, making it harder for the heart to pump blood. CAMZYOSTM is the first Canadian-approved allosteric and selective cardiac myosin inhibitor that targets the underlying pathophysiology of oHCM.
Hypertrophic cardiomyopathy (HCM) is the most common familial heart disease, occurring in about 1 in 500 individuals and affects males and females of all ages and ethnic backgrounds.